Welcome to our dedicated page for Opko Health SEC filings (Ticker: OPK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OPKO Health’s filings can feel like two companies in one: a nationwide genetics lab and a global pharmaceutical innovator. Digging through a 300-page disclosure to spot how BioReference’s testing volumes offset R&D spend—or to see when executives buy shares before an FDA catalyst—takes time. That is why investors search for “OPKO Health SEC filings explained simply” and often end up buried in footnotes.
Stock Titan solves this pain. Our AI parses every OPKO Health annual report 10-K simplified, flags segment revenue in the OPKO Health quarterly earnings report 10-Q filing, and delivers instant context for each OPKO Health 8-K material events explained. Need real-time alerts? We stream OPKO Health Form 4 insider transactions real-time so you never miss a trade. Whether you’re understanding OPKO Health SEC documents with AI for pipeline milestones or comparing cash burn trends, our platform turns dense pages into clear insights.
Here’s what you’ll find on this page:
- OPKO Health insider trading Form 4 transactions & OPKO Health executive stock transactions Form 4
- OPKO Health earnings report filing analysis drawn from 10-Qs and management commentary
- OPKO Health proxy statement executive compensation details, from equity grants to bonus metrics
- AI-powered summaries, red-flag highlights, and filing-to-filing comparisons
- Real-time EDGAR updates across all forms—10-K, 10-Q, 8-K, S-3, SC 13G, and more
Stop scrolling through PDFs line by line. Stock Titan’s expert analysis translates OPKO Health’s complex lab operations, global manufacturing notes, and drug-development disclosures into the actionable data investors actually use.
Phillip Frost M.D. and related entities reported multiple dispositions of OPKO HEALTH, INC. (OPK) common stock on 08/18/2025. The Form 4 shows a reported sale (transaction code G) of 440,000 shares for $0 and additional dispositions of 3,568,951 shares. Following the reported transactions, the filing lists 214,236,448 shares and 30,127,177 shares held indirectly by affiliated trusts and entities, with ownership described in footnotes clarifying trustee/beneficiary relationships. The filing is signed by Phillip Frost, M.D., individually and as trustee, indicating the report covers both his individual and related trust holdings.
Phillip Frost, M.D., in his capacities as CEO & Chairman, director and reported 10% owner, disclosed multiple changes in his OPKO Health (OPK) holdings. The filing shows on 08/08/2025 a purchase of 675,000 shares at $1.32 per share and a reported disposition of 3,568,951 shares. Following the reported transactions the Form lists indirect beneficial ownership amounts of 214,676,448 shares and 30,127,177 shares, each referenced to separate footnotes.
The footnotes explain these shares are held through Frost-controlled entities and trusts (Frost Gamma Investments Trust and Frost Nevada Investments Trust) with Dr. Frost acting as trustee or related party; the filing states he disclaims beneficial ownership except to the extent of any pecuniary interest. The report is a Section 16 Form 4 disclosure of insider activity and trust relationships only.
FAQ
What is the current stock price of Opko Health (OPK)?
What is the market cap of Opko Health (OPK)?
